Abdelkader NF, Safar MM, Salem HA (2016) Ursodeoxycholic acid ameliorates apoptotic Cascade in the Rotenone Model of Parkinson’s Disease. Modulation Mitochondrial Perturbations Mol Neurobiol 53(2):810–817

Article  CAS  PubMed  Google Scholar 

Ackerman HD, Gerhard GS (2016) Bile acids in neurodegenerative disorders. Front Aging Neurosci 8:263

Article  PubMed  PubMed Central  Google Scholar 

Ahmad MH, Rizvi MA, Ali M, Mondal AC (2023) Neurobiology of depression in Parkinson’s disease: insights into epidemiology, molecular mechanisms and treatment strategies. Ageing Res Rev 85:101840

Article  CAS  PubMed  Google Scholar 

Alharbi B, Al-Kuraishy HM, Al-Gareeb AI, Elekhnawy E, Alharbi H, Alexiou A, Papadakis M, Batiha GE (2024) Role of GABA pathway in motor and non-motor symptoms in Parkinson’s disease: a bidirectional circuit. Eur J Med Res 29(1):205

Article  PubMed  PubMed Central  Google Scholar 

Almeida-Bezerra JW, Rodrigues FC, Lima Bezerra JJ, Vieira Pinheiro AA, Almeida de Menezes S, Tavares AB, Costa AR, Bezerra Morais-Braga P, Melo Coutinho HD, Teixeira de Albergaria E, Meiado MV, Siyadatpanah A, Kim B, Morais de Oliveira AF (2022) Traditional uses, phytochemistry, and bioactivities of mesosphaerum suaveolens (L.) Kuntze. Evid Based Complement Alternat Med 2022: 3829180

Amirian R, Badrbani MA, Derakhshankhah H, Izadi Z, Shahbazi MA (2023) Targeted protein degradation for the treatment of Parkinson’s disease: advances and future perspective. Biomed Pharmacother 166:115408

Article  CAS  PubMed  Google Scholar 

Bell SM, Barnes K, Clemmens H, Al-Rafiah AR, Al-Ofi EA, Leech V, Bandmann O, Shaw PJ, Blackburn DJ, Ferraiuolo L, Mortiboys H (2018) Ursodeoxycholic acid improves mitochondrial function and redistributes Drp1 in fibroblasts from patients with either sporadic or familial Alzheimer’s Disease. J Mol Biol 430(21):3942–3953

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bloem BR, Okun MS, Klein C (2021) Parkinson’s Disease Lancet 397(10291):2284–2303

CAS  PubMed  Google Scholar 

Carling PJ, Mortiboys H, Green C, Mihaylov S, Sandor C, Schwartzentruber A, Taylor R, Wei W, Hastings C, Wong S, Lo C, Evetts S, Clemmens H, Wyles M, Willcox S, Payne T, Hughes R, Ferraiuolo L, Webber C, Hide W, Wade-Martins R, Talbot K, Hu MT, Bandmann O (2020) Deep phenotyping of peripheral tissue facilitates mechanistic disease stratification in sporadic Parkinson’s disease. Prog Neurobiol 187:101772

Article  CAS  PubMed  Google Scholar 

Castro-Caldas M, Carvalho AN, Rodrigues E, Henderson CJ, Wolf CR, Rodrigues CM, Gama MJ (2012) Tauroursodeoxycholic acid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson’s disease. Mol Neurobiol 46(2):475–486

Article  CAS  PubMed  Google Scholar 

Cattaneo C, Jost WH (2023) Pain in Parkinson’s Disease: pathophysiology, classification and treatment. J Integr Neurosci 22(5):132

Article  PubMed  Google Scholar 

Chahine LM, Merchant K, Siderowf A, Sherer T, Tanner C, Marek K, Simuni T (2023) Proposal for a Biologic Staging System of Parkinson’s Disease. J Parkinsons Dis 13(3):297–309

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chaudhuri KR, Azulay JP, Odin P, Lindvall S, Domingos J, Alobaidi A, Kandukuri PL, Chaudhari VS, Parra JC, Yamazaki T, Oddsdottir J, Wright J, Martinez-Martin P (2024) Economic Burden of Parkinson’s Disease: A Multinational. Real-World, Cost-of-Illness Study. Drugs Real World Outcomes

Google Scholar 

Cuevas E, Burks S, Raymick J, Robinson B, Gómez-Crisóstomo NP, Escudero-Lourdes C, Lopez AGG, Chigurupati S, Hanig J, Ferguson SA, Sarkar S (2022) Tauroursodeoxycholic acid (TUDCA) is neuroprotective in a chronic mouse model of Parkinson’s disease. Nutr Neurosci 25(7):1374–1391

Article  CAS  PubMed  Google Scholar 

Daruich A, Picard E, Boatright JH, Behar-Cohen F (2019) Review: the bile acids urso- and tauroursodeoxycholic acid as neuroprotective therapies in retinal disease. Mol Vis 25:610–624

CAS  PubMed  PubMed Central  Google Scholar 

Daruich A, Picard E, Guégan J, Jaworski T, Parenti L, Delaunay K, Naud MC, Berdugo M, Boatright JH, Behar-Cohen F (2022) Comparative analysis of Urso- and Tauroursodeoxycholic Acid Neuroprotective effects on Retinal Degeneration models. Pharmaceuticals (Basel) 15(3):334

Day JO, Mullin S (2021) The genetics of Parkinson’s disease and implications for clinical practice. Genes (Basel) 12(7)

De Miranda BR, Goldman SM, Miller GW, Greenamyre JT, Dorsey ER (2022) Preventing Parkinson’s disease: an environmental agenda. J Parkinsons Dis 12(1):45–68

Article  PubMed  PubMed Central  Google Scholar 

de Oliveira Junior ER, Truzzi E, Ferraro L, Fogagnolo M, Pavan B, Beggiato S, Rustichelli C, Maretti E, Lima EM, Leo E, Dalpiaz A (2020) Nasal administration of nanoencapsulated geraniol/ursodeoxycholic acid conjugate: towards a new approach for the management of Parkinson’s disease. J Control Release 321:540–552

Article  PubMed  Google Scholar 

El-Hamoly T, Abd El-Rahman SS, Al-Abyad M (2019) Potential effects of ursodeoxycholic acid on accelerating cutaneous wound healing. PLoS ONE 14(12):e0226748

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fonseca I, Gordino G, Moreira S, Nunes MJ, Azevedo C, Gama MJ, Rodrigues E, Rodrigues CMP, Castro-Caldas M (2017) Tauroursodeoxycholic acid protects against mitochondrial dysfunction and cell death via Mitophagy in Human Neuroblastoma cells. Mol Neurobiol 54(8):6107–6119

Article  CAS  PubMed  Google Scholar 

Gasser T (2023) Genetic testing for Parkinson’s disease in clinical practice. J Neural Transm (Vienna) 130(6):777–782

Article  CAS  PubMed  Google Scholar 

Goossens JF, Bailly C (2019) Ursodeoxycholic acid and cancer: from chemoprevention to chemotherapy. Pharmacol Ther 203:107396

Article  CAS  PubMed  Google Scholar 

Graham SF, Rey NL, Ugur Z, Yilmaz A, Sherman E, Maddens M, Bahado-Singh RO, Becker K, Schulz E, Meyerdirk LK, Steiner JA, Ma J, Brundin P (2018) Metabolomic Profiling of Bile Acids in an Experimental Model of Prodromal Parkinson’s Disease. Metabolites 8(4):71

Grant SM, DeMorrow S (2020) Bile acid signaling in neurodegenerative and neurological disorders. Int J Mol Sci 21(17)

Hayes MT (2019) Parkinson’s disease and parkinsonism. Am J Med 132(7):802–807

Article  PubMed  Google Scholar 

Hill DR, Huters AD, Towne TB, Reddy RE, Fogle JL, Voight EA, Kym PR (2023) Parkinson’s Disease: advances in treatment and the syntheses of various classes of Pharmaceutical Drug Substances. Chem Rev 123(23):13693–13712

Article  CAS  PubMed  Google Scholar 

Hofmann AF (1994) Pharmacology of ursodeoxycholic acid, an enterohepatic drug. Scand J Gastroenterol Suppl 204:1–15

Article  CAS  PubMed  Google Scholar 

Huang F (2021) Ursodeoxycholic acid as a potential alternative therapeutic approach for neurodegenerative disorders: effects on cell apoptosis, oxidative stress and inflammation in the brain. Brain Behav Immun Health 18:100348

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang L, Wei W, Huang X, Li X, Liu H, Gui L, Jiang J, Wan L, Zhou X, Ding J, Jiang X, Zhang B, Lan K (2023) High-fat diets enhance and delay ursodeoxycholic acid absorption but elevate circulating hydrophobic bile salts. Front Pharmacol 14:1168144

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jankovic J, Tan EK (2020) Parkinson’s disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry 91(8):795–808

Article  PubMed  Google Scholar 

Jiang C, Shen D, Li K, Wang H, Sang W, Qi H (2022) Protective effects of Ursodeoxycholic Acid against oxidative stress and Neuroinflammation through Mitogen-activated protein kinases pathway in MPTP-Induced Parkinson Disease. Clin Neuropharmacol 45(6):168–174

Article  CAS  PubMed  Google Scholar 

Jung HW, Hwang JH (2021) Anticancer effects of ursi fel extract and its active compound, ursodeoxycholic acid. FRO Anaplastic Thyroid Cancer Cells Molecules 26(17)

Khalaf K, Tornese P, Cocco A, Albanese A (2022) Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases. Transl Neurodegener 11(1):33

Article  CAS  PubMed  PubMed Central  Google Scholar 

Klein C, Schlossmacher MG (2007) Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder. Neurology 69(22):2093–2104

Article  PubMed  Google Scholar 

Kola S, Subramanian I (2023) Updates in Parkinson’s Disease Integrative therapies: an evidence-based review. Curr Neurol Neurosci Rep 23(11):717–726

Article